Home · Peptide Library · Wegovy
Wegovy
Wegovy is the FDA-approved weight-loss drug from Novo Nordisk. It's a higher-dose form of semaglutide, the same active ingredient in Ozempic, approved specifically for chronic weight management.
- Active ingredient
- Semaglutide
- Prescribed dose
- 2.4 mg weekly (titrated)
- Manufacturer
- Novo Nordisk
- FDA approved
- 2021 · Weight management
Dosing requires prescription and clinical supervision. Talk to your healthcare provider about whether Wegovy is right for you.
Quick Answer
Wegovy is FDA-approved for weight loss. People on it lose about 15% of their body weight over 68 weeks. If you weigh 200 pounds, that's 30 pounds. It's the same drug as Ozempic at a higher dose, approved for weight management instead of diabetes. The dose is semaglutide 2.4mg weekly. A 2023 cardiovascular trial also showed Wegovy cut major heart events by 20% in adults with obesity and existing heart disease. Below: what the trials actually show, how it compares to Zepbound, and the side effects worth knowing.
What is Wegovy?
Wegovy is the brand-name version of semaglutide 2.4mg made by Novo Nordisk for chronic weight management. The FDA approved it in 2021. To qualify, you need a BMI of 30 or higher, or 27 or higher plus a weight-related condition. That includes high blood pressure, type 2 diabetes, and sleep apnea. Wegovy is the same active ingredient as Ozempic, just at a higher dose for a different reason. Ozempic treats diabetes. Wegovy treats obesity.
How it works
Wegovy works by mimicking a hormone your gut already makes when you eat. The hormone is called GLP-1, and one of its jobs is telling your brain you're full. Wegovy is a long-lasting copy of GLP-1. It activates the same receptor more strongly than your body's own GLP-1. And it stays in your system for about a week per dose. The result: less appetite, slower digestion, and steadier blood sugar. In the FDA-approval trial, people on Wegovy lost about 15% of their body weight over 68 weeks. If you weigh 200 pounds, that's roughly 30 pounds.
How Wegovy compares
Wegovy vs Ozempic
Same drug, different dose, different FDA approval. Here's what that actually means for you.
Wegovy and Ozempic are the same drug. That drug is semaglutide, made by Novo Nordisk. The difference is the dose and what each is FDA-approved for. Ozempic is approved for type 2 diabetes at 0.5mg, 1mg, or 2mg weekly. Wegovy is approved for chronic weight management at the higher 2.4mg weekly dose. What this means for you. If you don't have diabetes and want to lose weight, Wegovy is the FDA-approved choice. If you have type 2 diabetes and you're trying to manage blood sugar, Ozempic is the standard. Both lower blood sugar. Both reduce appetite. Wegovy produces more weight loss in trials because the dose is higher.
Wegovy vs Zepbound
The two FDA-approved chronic-weight-management options. Here's where each wins.
Wegovy and Zepbound are both FDA-approved for chronic weight management. Zepbound produces more weight loss. In a 2025 head-to-head trial, people on Zepbound lost about 20% of their body weight at 72 weeks. People on Wegovy lost about 14%. If you weigh 200 pounds, that's 40 pounds versus 28. Why the gap? Wegovy mimics one of your body's natural fullness signals: GLP-1. Zepbound mimics two at once: GLP-1 plus GIP. The second signal adds extra appetite suppression that GLP-1 alone doesn't. What Wegovy still wins on. The strongest cardiovascular evidence. A 2023 trial enrolled 17,604 adults with obesity and existing heart disease. Wegovy cut their major heart events by 20% over about three years. Zepbound has its own heart trial running, but the data isn't out yet. What this means for you. If maximum weight loss is the goal and you don't have established heart disease, Zepbound is the stronger choice. If you have heart disease and obesity, Wegovy is the option with proven heart benefit today.
Approval status
Wegovy got FDA approval in 2021 for chronic weight management. The STEP trial program established efficacy across multiple groups. STEP 1 covered people with obesity. STEP 2 covered people with type 2 diabetes. STEP 4 covered weight maintenance after initial loss. STEP 8 was the head-to-head against Saxenda. The 2023 SELECT trial added a major finding. In adults with obesity and existing heart disease, Wegovy cut major cardiovascular events by 20% over about 40 months. The FDA expanded the label in 2024 to include cardiovascular risk reduction in that population.
Who should not take Wegovy
This page is informational only. Whether Wegovy is appropriate for you depends on your full medical history, current medications, and personal risk factors. Discuss with your healthcare provider for a personalized assessment.
Emerging safety evidence
Bone mineral density emerged as a consideration in a 2026 head-to-head retrospective (Liu et al., J Clin Endocrinol Metab). The study followed 255 GLP-1 RA users against 255 matched controls over 17 months. In people without diabetes, which is Wegovy's main population, the GLP-1 group lost modestly more bone at the total hip. The drop was -1.0% versus -0.6% in controls. In people with diabetes, bone loss was similar between groups. Within the GLP-1 group, bone loss correlated with weight loss. That suggests the effect is weight-loss-mediated rather than a direct drug action. The pattern matches what's seen with bariatric surgery and severe caloric restriction. Fracture-outcome data is still maturing. We don't know yet whether the bone-density signal becomes a fracture problem. Particularly relevant if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia, or prior osteoporosis.
Common questions
Is Wegovy the same as Ozempic?
Same drug, different dose, different FDA approval. Both are semaglutide made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes at doses up to 2mg per week. Wegovy is FDA-approved for chronic weight management at the higher 2.4mg dose. If you don't have diabetes, only Wegovy is FDA-approved for weight loss.
How much weight do you lose on Wegovy?
About 15% of your body weight over 68 weeks in the FDA-approval trial. If you weigh 200 pounds, that's roughly 30 pounds. About 86% of people lost at least 5%. About 32% lost 20% or more. Most weight loss happens in the first 12 months. Discontinuation reverses about two-thirds of the loss within a year if you stop the drug.
What are the side effects of Wegovy?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation. They tend to be worst at dose escalation and ease over a few weeks. Less common but serious: gallbladder disease, pancreatitis. A 2026 retrospective also showed modest extra bone-density loss in adults without diabetes who lost weight on a GLP-1. Fracture-outcome data isn't there yet. Particularly worth knowing if you're at baseline fracture risk: post-menopausal, older adult, prior osteopenia or osteoporosis.
How long does Wegovy take to work?
You'll start losing weight within the first few weeks. But most people don't see meaningful results until they reach the full 2.4mg dose. The standard ramp-up takes 16-20 weeks: 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg. The slow ramp lets your body adjust to the gut side effects. Peak weight loss in the trials happened around 60-68 weeks. If you're not losing 5% of body weight by month 6, the FDA label suggests reconsidering treatment.
What other GLP-1 options exist besides Wegovy?
Ozempic is the same molecule (semaglutide) at a lower dose, approved for type 2 diabetes. Zepbound (tirzepatide) is a dual-receptor GLP-1 that produces more weight loss in head-to-head trials. Saxenda (liraglutide) is a daily injection with smaller weight-loss effect. Retatrutide is an investigational triple-receptor GLP-1 in Phase 3 trials.
Can I switch from Ozempic or Saxenda to Wegovy?
Yes. Many people switch. From Ozempic, you're already on semaglutide. Switching to Wegovy is mostly a dose change to 2.4mg under your prescriber's plan. The ramp-up is usually faster than starting fresh because your body already tolerates semaglutide. From Saxenda (daily liraglutide), you're switching drugs and dosing schedules. The ramp-up starts at 0.25mg weekly, same as a fresh start. Either way, expect gut side effects to flare during the transition.
Full research profile
The full semaglutide research profile covers the complete STEP trial program, SUSTAIN cardiovascular data, SELECT outcomes, mechanism of action, and comparison with tirzepatide and retatrutide.
Wegovy and Ozempic share the same active ingredient: semaglutide. The full PSI semaglutide page covers the trial data side by side. It also covers the SELECT cardiovascular outcomes in detail, the bone density signal, and how the evidence compares against tirzepatide and retatrutide.
View full Semaglutide research profile →Comparisons
Related brands
Related research
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.